CoChat

MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs

Open access
Pyzer, A R, Stroopinsky, D, Rosenblatt, J, Anastasiadou, E, Rajabi, H, Washington, A, Tagde, A, Chu, J-H, Coll, M, Jiao, A L, Tsai, L T, Tenen, D E, Cole, L, Palmer, K, Ephraim, A, Leaf, R K, Nahas, M, Apel, A, Bar-Natan, M, Jain, S, McMasters, M, Mendez, L, Arnason, J, Raby, B A, Slack, F, Kufe, D, Avigan, D · 2017 · Leukemia
Cited by 76

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

The PD-L1/PD-1 pathway is a critical component of the immunosuppressive tumor microenvironment in acute myeloid leukemia (AML), but little is known about its regulation. We investigated the role of the MUC1 oncoprotein in modulating PD-L1 expression in AML. Silencing of MUC1 in AML cell lines suppressed PD-L1 expression without a decrease in PD-L1 mRNA levels, suggesting a post-transcriptional mechanism of regulation. We identified the microRNAs miR-200c and miR-34a as key regulators of PD-L1 expression in AML. Silencing of MUC1 in AML cells led to a marked increase in miR-200c and miR-34a levels, without changes in precursor microRNA, suggesting that MUC1 might regulate microRNA-processing. MUC1 signaling decreased the expression of the microRNA-processing protein DICER, via the suppression of c-Jun activity. NanoString (Seattle, WA, USA) array of MUC1-silenced AML cells demonstrated an increase in the majority of probed microRNAs. In an immunocompetent murine AML model, targeting of MUC1 led to a significant increase in leukemia-specific T cells. In concert, targeting MUC1 signaling in human AML cells resulted in enhanced sensitivity to T-cell-mediated lysis. These findings suggest MUC1 is a critical regulator of PD-L1 expression via its effects on microRNA levels and represents a potential therapeutic target to enhance anti-tumor immunity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/leu.2017.163

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 76

Metadata

Authors
Pyzer, A. R., Stroopinsky, D., Rosenblatt, J., Anastasiadou, E., Rajabi, H., Washington, A., Tagde, A., Chu, J.-H., Coll, M., Jiao, A. L., Tsai, L. T., Tenen, D. E., Cole, L., Palmer, K., Ephraim, A., Leaf, R. K., Nahas, M., Apel, A., Bar-Natan, M., Jain, S., McMasters, M., Mendez, L., Arnason, J., Raby, B. A., Slack, F., Kufe, D., & Avigan, D.
Venue
Leukemia
Published
2017-05-30
Volume
31
Issue
12
Pages
2780-2790
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
OpenAlex
W2619061518
Cited by
76
References
5
FWCI
4.09
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs. https://app.cochat.ai/papers/10.1038/leu.2017.163
The paper
Pyzer, A. R., Stroopinsky, D., Rosenblatt, J., Anastasiadou, E., Rajabi, H., Washington, A., Tagde, A., Chu, J.-H., Coll, M., Jiao, A. L., Tsai, L. T., Tenen, D. E., Cole, L., Palmer, K., Ephraim, A., Leaf, R. K., Nahas, M., Apel, A., Bar-Natan, M., . . . Avigan, D. (2017). MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs. Leukemia. https://doi.org/10.1038/leu.2017.163

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.